Repros Therapeutics Inc. (RPRX) Short Interest Up 165.8% in June
Repros Therapeutics Inc. (NASDAQ:RPRX) was the recipient of a large increase in short interest in the month of June. As of June 30th, there was short interest totalling 1,790,958 shares, an increase of 165.8% from the June 15th total of 673,714 shares. Currently, 6.2% of the shares of the stock are short sold. Based on an average daily trading volume, of 1,094,710 shares, the days-to-cover ratio is presently 1.6 days.
An institutional investor recently raised its position in Repros Therapeutics stock. Renaissance Technologies LLC increased its stake in shares of Repros Therapeutics Inc. (NASDAQ:RPRX) by 1.5% during the first quarter, according to its most recent filing with the SEC. The fund owned 727,113 shares of the biotechnology company’s stock after buying an additional 10,700 shares during the period. Renaissance Technologies LLC owned approximately 2.73% of Repros Therapeutics worth $873,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 21.71% of the company’s stock.
Repros Therapeutics (NASDAQ RPRX) opened at 0.5789 on Friday. The firm has a 50-day moving average of $0.51 and a 200 day moving average of $1.03. The company’s market capitalization is $15.48 million. Repros Therapeutics has a 12-month low of $0.33 and a 12-month high of $2.48.
Repros Therapeutics (NASDAQ:RPRX) last announced its quarterly earnings results on Tuesday, May 9th. The biotechnology company reported ($0.22) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.14) by $0.08. Repros Therapeutics had a negative net margin of 49,564.86% and a negative return on equity of 276.50%. The company had revenue of $0.01 million for the quarter. Analysts expect that Repros Therapeutics will post ($0.76) EPS for the current fiscal year.
Repros Therapeutics Company Profile
Repros Therapeutics, Inc is a biopharmaceutical company focused on the development of new drugs to treat hormonal and reproductive system disorders. The Company’s product candidates include enclomiphene, which is a single isomer of clomiphene citrate, an orally active small molecule compound, and Proellex, which is an orally administered selective blocker of the progesterone receptor in women, for the treatment of uterine fibroids and endometriosis.
Receive News & Ratings for Repros Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repros Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.